Shelly Allen

Affiliations: 
University of Bristol, Bristol, England, United Kingdom 
Area:
Alzheimer's disease (pathophysiology, therapeutics), cholinergic systems
Website:
http://www.bristol.ac.uk/neuroscience/research/groups/pidetails/60
Google:
"Shelly Allen"
Mean distance: 106866
 
Cross-listing: Alzheimer's Tree

BETA: Related publications

Publications

You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Shoemark DK, Williams C, Fahey MS, et al. (2015) Design and nuclear magnetic resonance (NMR) structure determination of the second extracellular immunoglobulin tyrosine kinase A (TrkAIg2) domain construct for binding site elucidation in drug discovery. Journal of Medicinal Chemistry. 58: 767-77
Allen SJ, Watson JJ, Shoemark DK, et al. (2013) GDNF, NGF and BDNF as therapeutic options for neurodegeneration. Pharmacology & Therapeutics. 138: 155-75
Frias B, Allen S, Dawbarn D, et al. (2013) Brain-derived neurotrophic factor, acting at the spinal cord level, participates in bladder hyperactivity and referred pain during chronic bladder inflammation. Neuroscience. 234: 88-102
Allen SJ, Watson JJ, Dawbarn D. (2011) The neurotrophins and their role in Alzheimer's disease. Current Neuropharmacology. 9: 559-73
McNamee KE, Burleigh A, Gompels LL, et al. (2010) Treatment of murine osteoarthritis with TrkAd5 reveals a pivotal role for nerve growth factor in non-inflammatory joint pain. Pain. 149: 386-92
Pinto R, Frias B, Allen S, et al. (2010) Sequestration of brain derived nerve factor by intravenous delivery of TrkB-Ig2 reduces bladder overactivity and noxious input in animals with chronic cystitis. Neuroscience. 166: 907-16
Masoudi R, Ioannou MS, Coughlin MD, et al. (2009) Biological activity of nerve growth factor precursor is dependent upon relative levels of its receptors. The Journal of Biological Chemistry. 284: 18424-33
Watson JJ, Allen SJ, Dawbarn D. (2008) Targeting nerve growth factor in pain: what is the therapeutic potential? Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy. 22: 349-59
Clewes O, Fahey MS, Tyler SJ, et al. (2008) Human ProNGF: biological effects and binding profiles at TrkA, P75NTR and sortilin. Journal of Neurochemistry. 107: 1124-35
Hatchett CS, Tyler S, Armstrong D, et al. (2007) Familial Alzheimer's disease presenilin 1 mutation M146V increases gamma secretase cutting of p75NTR in vitro. Brain Research. 1147: 248-55
See more...